ANEB
Anebulo Pharmaceuticals, Inc.
$0.34
-0.01 (-1.75%)
At close · Jul 8
Market Cap
$13.70M
Shares
40,784,731
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.34
Open$0.34
Day$0.34–0.34
52W$0.01–3.42
Avg vol 30d3K
Short int6K · 0.0% float · 1.0d
Short vol30%
Last earningsFeb 12, 2026
DataMay 2021–Jul 2026
Filing10-Q · Feb 12
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−73%
below
Price vs 50-day avg
−22%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
10%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−7%
trailing
6-month return
−70%
trailing
YTD return
−67%
this year
Relative strength
−77%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.01% of float · ▼ -1.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
19 holders — mid 3-yr range
Squeeze score
41
elevated · 0–100
Fundamentals
EPS growth
+22%
Y/Y
Balance sheet
$11.6M
net cash
Quant / Vol
risk profile
Volatility
149%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
15.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
filed Feb 12, 2026
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−73%
Bearish
Price vs 50-day avg
−22%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
10%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.01% of float · ▼ -1.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
19 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 10%
52-wk high $3
vs 200-day avg -73%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANEB
this stock
Anebulo Pharmaceuticals, Inc.
|
$13.70M | -66.7% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANEB | -14.9% | -6.7% | -69.7% | -14.9% | -66.7% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -14.8% | -7.5% | -77.2% | -14.8% | -76.0% |